Abnormalities in the NF-κB family and related proteins in endometrial carcinoma

Journal of Pathology

Volumn 204, Issue 5, 2004, Pages 569-577

  Pallares, Judit ^a   Martínez Guitarte, Jose Luis ^a   Dolcet, Xavier ^a   Llobet, David ^a   Rue, Montserrat ^a   Palacios, José ^b   Prat, Jaime ^c   Matias Guiu, Xavier ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b Lab of Breast Gynaecological Cancer   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Endometrial carcinoma; Molecular pathology; NF B; Tissue microarray

Indexed keywords

BETA CATENIN; CYCLIN D1; FLICE INHIBITORY PROTEIN; I KAPPA B; I KAPPA B ALPHA; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; PARAFFIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 3; PROTEIN BCL XL; PROTEIN P52; PROTEIN P60; RAS PROTEIN; STEROID RECEPTOR; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELB; CANCER ANTIBODY; CTNNB1 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; ESTROGEN RECEPTOR; MICROSATELLITE DNA; PHOSPHATASE; PROGESTERONE RECEPTOR; PTEN PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; CORRELATION FUNCTION; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; FEMALE; GENE CONSTRUCT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; MULTIGENE FAMILY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN MICROARRAY; PROTEIN TARGETING; REGULATORY MECHANISM; STATISTICAL SIGNIFICANCE; ADENOCARCINOMA; CANCER STAGING; CYTOPLASM; ENDOMETRIUM TUMOR; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METHODOLOGY; ONCOGENE RAS; PATHOLOGY; TISSUE MICROARRAY;

ADENOCARCINOMA; ANTIBODIES, NEOPLASM; BETA CATENIN; CYTOPLASM; CYTOSKELETAL PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; I-KAPPA B PROTEINS; IMMUNOHISTOCHEMISTRY; MICROSATELLITE REPEATS; NEOPLASM PROTEINS; NEOPLASM STAGING; NF-KAPPA B; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 9744257018     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1666     Document Type: Article

References (52)

1. Bockman JV. Two pathogenic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-17.
2. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 1997; 81: 228-232.
3. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995; 26: 1268-1274.
4. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32: 569-577.
5. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occurs early in their pathogenesis. Am J Pathol 1997; 150: 177-185.
6. Tritz; D, Pieretti M, Turner S, et al. Loss of heterozygosity in usual and special variant carcinomas of the endometrium. Hum Pathol 1997; 28: 607-612.
7. Burcks RT, Kessis ThD, Cho KR, et al. Microsatellite instability in endometrial carcinoma. Oncogene 1994; 9: 1163-1166.
8. Caduff RF, Johnston CM, Svoboda-Newman SM, et al. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996; 148: 1671-1678.
9. Esteller M, Catasus LI, Matias-Gum X, et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999; 155: 1767-1772.
10. Catasús LI, Machin P, Matias-Guiu X, et al. Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998; 29: 1160-1164.
11. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997; 57: 3935-3940.
12. Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997; 17 143-144.
13. Levine RL, Cargile CB, Blazes MS, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998; 58: 3254-3258.
14. Bussaglia E, del Rio E, Matias-Guiu X, Prat J. PTEN mutations in endometrial carcinomas: a molecular and clinico-pathologic analysis of 38 cases. Hum Pathol 2000; 31: 312-317.
15. Lagarda H, Catasus L, Arguelles R, Matias-Guiu X, Prat J. K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 2001; 193: 193-199.
16. Fukuchi T, Sakamoto M, Tsuda H, et al. Beta-catenin mutations in carcinoma of the uterine endometrium. Cancer Res 1998; 58: 3526-3528.
17. Kobayashi K, Sagae S, Nishioka Y, et al. Mutations of the beta-catenin gene in endometrial carcinomas. Jpn J Cancer Res 1999; 90: 55-59.
18. Palacios J, Moreno-Bueno G, Catasus LI, et al. Beta and gamma-catenin expression in endometrial carcinoma: relationship with clinicopathological features and microsatellite instability. Virchows Arch 2001; 438: 464-469.
19. Machin P, Catasus L, Pons C, Muñoz J, Matias-Guiu X, Prat J. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol 2002; 33: 206-212.
20. Moreno-Bueno G, Hardisson D, Sanchez C, et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002; 14(21): 7981-7990.
21. Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-κB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999; 45: 7-17.
22. Baldwin Jr AS. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996; 16: 649-683.
23. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-260.
24. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-κB. Annu Rev Cell Biol 1994; 10: 405-455.
25. St-Germain ME, Gagnon V, Asselin E. Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway. Mol Cancer 2004; 3: 7.
26. Arsura M, Mercurio F, Oliver AL, Thorgeirsson SS, Sonenshein GE. Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells. Mol Cell Biol 2000; 20: 5381-5391.
27. Beraud C, Henzel WJ, Baeuerle PA. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation. Proc Natl Acad Sci USA 1999; 96: 429-434.
28. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-390.
29. Bours V, Franzoso G, Azarenko V, et al. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 1993; 72: 729-739.
30. Gilmore TD, Koedood M, Piffat KA, White DW. Rel/NF-kB/IkB proteins and cancer. Oncogene 1996; 13: 1367-1378.
31. Neri A, Chang CC, Lombardi L, et al. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50. Cell 1991; 67: 1075-1087.
32. Fracchiolla NS, Lombardi L, Salina M, et al. Structural alterations of the NF-κB transcription factor lyt-10 in lymphoid malignancies. Oncogene 1993; 8: 2839-2845.
33. Liptay S, Seriu T, Bartram CR, Schmid RM. Germline configuration of nfkb2, c-rel and bcl-3 in childhood acute lymphoblastic leukemia (ALL). Leukemia 1997; 11: 1364-1366.
34. Cabannes E, Khan G, Aillet F, Jarrett FF, Hay RT. Mutations in the IkBα gene in Hodgkin's disease suggest a tumor suppressor role for IκBα. Oncogene 1999; 18: 3063-3070.
35. Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B-and I kappa B-related proteins in tumor cell lines. Biochem Pharmacol 1994; 47: 145-149.
36. Vasudevan KM, Gurumurthy S, Rangnekar VM. Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol 2004; 24: 1007-1021.
37. Ismail HA, Lessard L, Mes-Masson AM, Saad F. Expression of NF-kappaB in prostate cancer lymph node metastases. Prostate 2004; 58: 308-313.
38. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997; 17: 3629-3639.
39. Liang JT, Huang KC, Jeng YM, Lee PH, Lai HS, Hsu HC. Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer. Br J Surg 2004; 91: 355-361.
40. Yoshimatsu K, Golijanin D, Paty PB, et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 2001; 7: 3971-3976.
41. St-Germain ME, Gagnon V, Mathieu J, Parent S, Asselin E. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells. Int J Oncol 2004; 24: 1311-1324.
42. Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K, Miyazaki K. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol 2002; 33: 213-219.
43. Vaskivuo TE, Stenback F, Tapanainen JS. Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma. Cancer 2002; 95: 1463-1471.
44. Sovak MA, Bellas RE, Kim DW, et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997; 100: 2953-2960.
45. Cogswell PC, Guttride DC, Funkhouser WK, Baldwin Jr AS. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 2000; 19: 1123-1131.
46. Chiao PJ, Miyamoto S, Verma IM. Autoregulation of I kappa B alpha activity. Proc Natl Acad Sci USA 1994; 91: 28-32.
47. McKeithan TW, Takimoto GS, Ohno H, et al. BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: a molecular and cytogenetic study. Genes Chromosomes Cancer 1997; 20: 64-72.
48. Bouts V, Franzoso G, Azarenko V, et al. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via associations with DNA-binding p50B homodimers. Cell 1993; 72: 729-739.
49. Zhang Q, Didonato JA, Karin M, McKeithan TW. BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteins. Mol Cell Biol 1994; 14: 3915-3926.
50. Moreno-Bueno G, Rodriguez-Perales S, Sanchez-Estevez C, et al. Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene 2003; 22: 6115-6118.
51. Millan O, Ballester A, Castrillo A, et al. H-Ras-specific activation of NF-kappaB protects NIH 3T3 cells against stimulus-dependent apoptosis. Oncogene 2003; 22: 477-483.
52. Evertsson S and Sun XF: protein expression of NF-kappaB in human colorectal adenocarcinoma. Int J Mol Med 2002; 10: 547-550.